Edge Rewrite
// HTMLRewriter · presentation

This page was redesigned at the edge.

Cloudflare fetched the original article and streamed it through HTMLRewriter to apply an entirely new visual system without rebuilding the source page.

// request.cf · coarse context

A page that knows where it met you.

Only coarse request metadata is shown. This demo does not display or persist visitor IP addresses.

Country
US
Cloudflare location
CMH
Connection
HTTP/2
Language
Not provided

Ray ID: a4247b03ab87d287

Jump to content

Genomic Health

From Wikipedia, the free encyclopedia
Genomic Health, Inc.
TypeSubsidiary
Nasdaq: GHDX
IndustryGenomics
FoundedAugust 2000; 26 years ago (2000-08), in Redwood City, California, U.S.
FounderRandy Scott
SuccessorExact Sciences
HeadquartersRedwood City, California, U.S.
Key people
ProductsOncotype DX
Number of employees
863 (2017)
Websitewww.genomichealth.com Edit this at Wikidata
Footnotes
[1][2][3]

Genomic Health, Inc. is a company focusing on genetic research specifically in cancer detection, based out of Redwood City, California.[2] The company was acquired by and merged with Exact Sciences Corporation in 2019.

History

[edit]

Genomic Health, Inc. was founded in 2000 by Randy Scott, who had previously founded and been CEO at Incyte.[4] He formed the company after a close friend was diagnosed with cancer and had the idea for treatment based on the specific genome of their tumor.[5]

By 2003 Genomic Health had developed Oncotype DX, a genomic assay that quantified the likelihood of breast cancer recurrence.[6] This development took the company over three years and US$30,000,000 to complete and then had to convince skeptics at the time of the validity of genetic testing.[6]

In July 2005 Genomic Health filed for an initial public offering to sell up to US$75,000,000 in common stock. Investors at the time already included Versant Ventures and Kleiner Perkins Caufield & Byers.[7] On September 29, 2005 it was listed on the NASDAQ with the symbol GHDX with the initial share price of US$12 for 5016722 shares.[8]

Genomic Health also started a subsidiary in 2010, Invitae, with the goal of aggregating multiple genetics tests. Invitae was spun off in 2012.[9]

The company expanded with international headquarters in Geneva Switzerland and UK headquarters in London in 2011.[10]

In July 2019, Exact Sciences announced that it was purchasing Genomic Health to increase the variety of medical tests they offer.[11]

See also

[edit]

References

[edit]
  1. ↑ "US SEC: Form 10-K Genomic Health, Inc". U.S. Securities and Exchange Commission. Retrieved April 3, 2018.
  2. 1 2 "GENOMIC HEALTH, INC". OpenCorporates. 13 December 2016. Retrieved 10 January 2017.
  3. ↑ Chaykowsk, Kathleen (10 April 2012). "CEO's dedication is behind Genomic Health's cancer tests". Peninsula Press. Retrieved 10 January 2017.
  4. ↑ Susan McKinnon; Sydel Silverman (1 June 2005). Complexities: Beyond Nature and Nurture. University of Chicago Press. p. 239. ISBN 978-0-226-50024-9. Retrieved 10 January 2017.
  5. ↑ Cook, Kevin (7 October 2013). "Genomic Health Has Sickly Stock Chart". Forbes. Retrieved 10 January 2017.
  6. 1 2 Chess, Robert; Denend, Lyn; Zenios, Stefanos (2006). "Genomic Health: Launching a Paradigm Shift ... and an Innovative New Test". Stanford Graduate School of Business. Retrieved 10 January 2017.
  7. ↑ Simmers, Tim (19 July 2005). "Genomic Health files for an IPO". East Bay Times. Retrieved 10 January 2017.
  8. ↑ "GENOMIC HEALTH INC (GHDX) IPO". NASDAQ. Retrieved 10 January 2017.
  9. ↑ Baxt, Josh. "Invitae CEO says the diagnostic company has big plans for genomic medicine". Breaking Media, Inc.
  10. ↑ "Company Timeline & Milestones". Genomic Health. Archived from the original on 30 July 2019. Retrieved 10 January 2017.
  11. ↑ Flanagan, Cristin; Ahmed, Nabila (29 July 2019). "Exact Sciences to Buy Genomic Health for About $2.8 Billion". Bloomberg News. Retrieved 30 July 2019.
[edit]
  • Official website Edit this at Wikidata
  • Business data for Genomic Health, Inc.: